Scientists Watch Alzheimer's Protein Clumping Being Reversed in Real Time — A First

An Oregon State University scientist and a team of undergraduate students have uncovered real-time insights into a chemical process linked with Alzheimer's disease, paving the way toward better drug designs. The researchers used a molecule-measuring technique called fluorescence anisotropy to observe in a laboratory setting how certain metals can promote the protein clumping that leads to the blocked neural pathways associated with Alzheimer's — and crucially, watched molecules known as chelators disrupt or reverse that clumping, second by second. Findings were published in the journal ACS Omega. Alzheimer's disease is the most common form of dementia, a chronic condition of impaired cognitive function that affects large numbers of older adults and their loved ones. According to the Centers for Disease Control and Prevention, Alzheimer's is the sixth-leading cause of death for people age 65 and older. In Alzheimer's patients, aggregations of amyloid-beta proteins interrupt brain cells' ability to communicate with each other. The brain needs certain metals to work properly, but problems arise when the metals are present in unbalanced quantities. 'Too many of some metal ions, like copper, can interact with amyloid-beta proteins in ways that lead to protein aggregation, but most experiments have only shown the end result, not the interactions and aggregation process itself,' said lead researcher Marilyn Rampersad Mackiewicz, a materials scientist and associate professor of chemistry at OSU. 'We developed a method that lets us observe those interactions live, second by second, and directly measure how different molecules interrupt or reverse them. It shifts the question from "does something work?" to "how does it work, and when?"' A chelator — whose name comes from the Greek word for claw — is a type of molecule able to bind with metal ions as if gripping them tightly. The study tested multiple chelators and found that some could effectively snatch up the problematic metal ions, though they varied in how selectively they worked. What makes this research particularly exciting is that it moves Alzheimer's drug research from looking at static snapshots to watching the full movie. By understanding exactly when and how protein clumping can be interrupted, scientists can design more targeted drugs that work at the right moment in the disease process. With over 55 million people worldwide living with dementia — a number expected to nearly triple by 2050 — any advance in understanding Alzheimer's mechanisms brings hope to millions of families. This real-time observation method could accelerate the development of treatments that don't just slow the disease, but actively reverse the damage.